Research suggests lack of diagnosis is primary barrier to treatmentResearchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.

Researchers have determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. If this disturbing trend continues, by 2030 less than 15 percent of liver-related deaths from HCV will be prevented by antiviral therapy.

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they are infected. If this disturbing trend continues, by 2030 less than 15% of liver-related deaths from ...

( Wiley-Blackwell ) Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. If this disturbing trend continues, by 2030 less than 15 percent of liver-related deaths from HCV will be prevented by antiviral therapy. This study, the first to analyze ...

Pharmasset, Inc. (Nasdaq: VRUS) announced that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.

New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in recent years should be a wake-up call that Congress needs to move urgently on bipartisan legislation to support new state-based detection, research, and surveillance efforts, the National Viral Hepatitis Roundtable (NVHR) said today.

Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C. An independent committee reviewed data from the first 100 subjects enrolled in the midstage... Liver - Hepatitis C - Hepatitis - Clinical trial - Health

(PhysOrg.com) -- Hepatitis C, a formidable virus that affects 130 million people worldwide, is nursing some pretty impressive bruises. By knocking out sections and subsections of one of its proteins, scientists reveal weak spots in the virus's armor and gain new momentum for developing drug targets for sufferers of the disease.

Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.

The Academy of Medical Science of the Democratic People's Republic of Korea (DPRK) said it had developed a new reagent "HCV-PHA" for diagnosis of hepatitis C virus antibody, official news agency KCNA reported on Thursday. The researchers said it is an ecto-diagnosis reagent for examining an antibody in blood by using an antigen related to the hepatitis C virus. The reagent was developed from a ...

WASHINGTON, Nov.

A novel vaccine, IC41, containing sections from the hepatitis C virus (HCV) has produced a modest, but apparently continuous, viral load decline in patients who already have hepatitis C.

Research and Markets (http://www.researchandmarkets.com/research/f6bf5e/hepatitis_c_virus) has announced the addition of the "Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities" report to their offering.

NEW YORK — Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical ...

Pharmasset, Inc. announced today that the enrollment of Cohort 2, led by its partner Roche, will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

Screening for Hepatitis C virus (HCV) infection among pregnant women on methadone maintenance treatment and their infants is inadequate, according to the authors of a study published in the Medical Journal of Australia.

Patients and caregivers for those with hepatitis C held a rally outside the Alameda County Public Health Department building today to protest the absence of testing and treatment services in the county and the state.

Even as awareness of hepatitis C grows, the scant resources devoted to its treatment are being slashed. by Julia Landau Dr. Diana Sylvestre is not an alarmist. But when it comes to the hepatitis C virus (HCV) — the country's number one blood-borne pathogen — she says we are in the midst of a grave public health crisis with Oakland as an epicenter. And that's inexcusable, she believes, because ...

According to the Public Health Department, 58 cases of chlamydia and 338 cases of hepatitis C have been diagnosed in Tuolumne County through September of this year. Public Health Officer Dr. Todd Stolp said the figures put the county at the mid-range in the state when the Sierra Conservation Center is taken into account. The prison accounts for around 40 percent of the county’s hepatitis cases ...

Safety monitors force change to mid-stage study of ITMN-191

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

( Wiley-Blackwell ) Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups. Study findings are presented in the December ...

Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies’ combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in ...

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups. Study findings are presented in the December issue of Liver ...

InterMune Inc. dipped on news that it would stop testing the highest dose in its ongoing Phase IIb study of protease inhibitor ITMN-191 in hepatitis C virus after reports of liver toxicity in three patients, offering a minor distraction for investors awaiting FDA word on the company's new drug application for fibrosis candidate pirfenidone.

A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). The study also found significantly higher plasma monounsaturated fatty acids in the blood of ...

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 -- a small molecule synthetic peptide with immunomodulating properties -- for the treatment of severe oral mucositis (OM) in patients with head and neck cancer.

Every 30 seconds someone in America files for bankruptcy because of a medical disaster. That's according to a Harvard study that found 62 percent of all bankruptcies can now be linked to a medical cause. But the one group of Americans that may be most affected by health reform that is unable to spend a single dollar on lobbying congress.

(ARA) - As we grow older, we look forward to the changes that life brings - retirement, grandchildren, financial security and travel. Other changes that we might not accept so readily are the aches, pains and mental slowdowns that leave us longing for the good old days of our youth.